Results 101 to 110 of about 843,559 (297)
Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor +12 more
wiley +1 more source
Background Anti-CD20 monoclonal antibodies are major therapeutic agents for patients with follicular lymphoma and work through complement-mediated cytotoxicity and antibody-dependent cellular cytotoxicity.
Mounia Sabrina Braza +3 more
doaj +1 more source
Cofetuzumab pelidotin (Cofe‐P) is an anti‐protein tyrosine kinase 7 (PTK7) antibody‐drug conjugate (ADC) being investigated for the treatment of adults with PTK7‐expressing, recurrent non‐small cell lung cancer (NSCLC). The first‐in‐human (FIH) trial demonstrated tolerability of dosages ≤ 2.8 mg/kg once every 3 weeks (Q3W) and ≤ 3.2 mg/kg Q2W ...
Carla Biesdorf +8 more
wiley +1 more source
Humanized Anti-TAG-72 Monoclonal Antibodies
The present invention relates to humanized antibodies specific to a tumor-associated glycoprotein, TAG-72, and anticancer compositions comprising the humanized antibodies.
홍효정 +3 more
core +1 more source
BACKGROUND: Antiglobulin responses are a significant limitation to the repeated use of murine monoclonal antibodies for treatment of transplant rejection.
Perpetua R.U.B. Rebello +4 more
core +1 more source
Exposure‐response analyses supported a favorable benefit‐risk profile of Dato‐DXd at 6 mg/kg Q3W in patients with advanced nonsquamous NSCLC. Datopotamab deruxtecan (Dato‐DXd) is a trophoblast cell‐surface antigen‐2 (TROP2)‐directed antibody‐drug conjugate (ADC) that has demonstrated clinical activity in patients with NSCLC who have received prior ...
Ying Hong +10 more
wiley +1 more source
Biomarkers of lung congestion and injury in acute heart failure
Abstract Acute heart failure (AHF) classification and management are primarily based on lung congestion and/or hypoperfusion. The quantification of the vascular and tissue lung damage is not standard practice though biomarkers of lung injury may play a relevant role in this context.
Marco Guazzi +9 more
wiley +1 more source
Humanized antibodies as potential drugs for therapeutic use
Antibodies have been used therapeutically to treat a variety of clinical conditions. The introduction of monoclonal antibodies (mAb) and, recently, engineered antibodies has greatly refined and expanded the therapeutic potential of this modality of ...
MERLUZZI S +4 more
core +1 more source
Validation of an LED fluorescence‐based parallel CE‐SDS method for monoclonal antibody size heterogeneity analysis, demonstrating specificity, accuracy, robustness, and precision (RSD < 1%, for monomeric purity and glycosylation). The method provides established UV‐based results while offering greater sensitivity, baseline stability, and substantially ...
Kyle D. Luttgeharm +3 more
wiley +1 more source

